Table 3. Proportion of responders per serogroup and per population and SBA GMT at 4 weeks after vaccination.
| Analyses | Dose Group | Proportion of Responders | SBA Titers four weeks after vaccination | |||
| n/N | % | 95% CI | GMT | 95% CI | ||
| Serogroup A | ||||||
| MITT | Full | 249/289 | 86.2 | 82.2–90.2 | 3607.1 | 2952.8–4406.3 |
| 1/5 dose | 173/224 | 77.2 | 71.7–82.7 | 2035.4 | 1600.1–2589.0 | |
| 1/10 dose | 159/230 | 69.1 | 63.2 -75.0 | 1367.6 | 1083.1–1726.8 | |
| PP | Full | 247/287 | 86.1 | 82.1–90.1 | 3612.6 | 2953.3–4419.1 |
| 1/5 dose | 172/222 | 77.5 | 72.0–83.0 | 2054.4 | 1612.2–2618.0 | |
| 1/10 dose | 159/229 | 69.4 | 63.5–75.3 | 1369.3 | 1083.3–1730.7 | |
| Non immune | Full | 140/148 | 94.6 | 91.0–98.2 | 1918.0 | 1426.0–2579.8 |
| 1/5 dose | 94/102 | 92.2 | 87.0–97.4 | 852.3 | 573.2–1267.5 | |
| 1/10 dose | 98/111 | 88.3 | 82.4–94.2 | 754.1 | 495.3–1148.1 | |
| Serogroup W135 | ||||||
| MITT | Full | 269/289 | 93.1 | 90.2–96.0 | 2190.3 | 1728.9–2774.6 |
| 1/5 dose | 212/224 | 94.6 | 91.7–97.5 | 2029.1 | 1573.7–2616.2 | |
| 1/10 dose | 220/231 | 95.2 | 92.5–97.9 | 2422.7 | 1979.9–2964.6 | |
| PP | Full | 267/286 | 93.4 | 90.5–96.3 | 2175.9 | 1714.2–2762.0 |
| 1/5 dose | 210/222 | 94.6 | 91.6–97.6 | 2041.6 | 1582.2–2634.5 | |
| 1/10 dose | 219/229 | 95.6 | 93.0–98.2 | 2426.3 | 1979.7–2973.7 | |
| Non immune | Full | 207/221 | 93.7 | 90.5–96.9 | 1539.5 | 1160.0–2043.2 |
| 1/5 dose | 168/178 | 94.4 | 91.0–97.8 | 1517.4 | 1129.3–2039.0 | |
| 1/10 dose | 172/177 | 97.2 | 94.8–99.6 | 2008.3 | 1583.0–2547.9 | |
| Serogroup C | ||||||
| MITT | Full | 259/284 | 91.2 | 87.9–94.5 | 1168.3 | 911.0–1498.2 |
| 1/5 dose | 179/222 | 80.6 | 75.4–85.8 | 472.1 | 332.3–670.6 | |
| 1/10 dose | 171/223 | 76.7 | 71.2–82.2 | 399.3 | 277.1–575.4 | |
| PP | Full | 257/282 | 91.1 | 87.8–94.4 | 1175.1 | 914.9–1509.3 |
| 1/5 dose | 177/220 | 80.4 | 75.2–85.6 | 467.3 | 328.0–665.8 | |
| 1/10 dose | 170/222 | 76.6 | 71.1–82.1 | 396.3 | 274.6–572.0 | |
| Non immune | Full | 252/271 | 93.0 | 90.0–96.0 | 1108.5 | 858.4–1431.5 |
| 1/5 dose | 172/211 | 81.5 | 76.3–86.7 | 412.2 | 288.2–589.6 | |
| 1/10 dose | 156/202 | 77.2 | 71.4–83.0 | 315.6 | 214.8–463.8 | |
| Serogroup Y | ||||||
| MITT | Full | 242/286 | 84.6 | 80.4–88.8 | 936.2 | 673.7–1301.0 |
| 1/5 dose | 185/224 | 82.6 | 77.7–87.5 | 772.7 | 529.2–1128.2 | |
| 1/10 dose | 194/231 | 84.0 | 79.3–88.7 | 822.6 | 569.8–1187.5 | |
| PP | Full | 240/284 | 84.5 | 80.3–88.7 | 924.2 | 663.8–1286.7 |
| 1/5 dose | 183/222 | 82.4 | 77.4–87.4 | 768.3 | 524.4–1125.6 | |
| 1/10 dose | 193/230 | 83.9 | 79.2–88.6 | 816.8 | 565.1–1180.8 | |
| Non immune | Full | 238/282 | 84.4 | 80.2–88.6 | 916.8 | 657.3–1278.8 |
| 1/5 dose | 175/214 | 81.8 | 76.7–86.9 | 687.5 | 466.1–1014.1 | |
| 1/10 dose | 191/228 | 83.8 | 79.0–88.6 | 798.1 | 551.1–1155.7 | |